New aspects of the treatment of endometrial hyperplastic processes and endometrial cancer

The study (93 patients, including 75 – with the endometrial hyperplastic process, 5 – with endometrial adenocarcinoma T1NxMx, 13 – with dysfunctional uterine bleeding of the premenopausal period) is devoted to the assessment of immunological disorders and imbalance of the receptor status of the endometrium and the effectiveness of their correction by the endogenous interferon inductor amixin. In the initial interferon status, there was a significant decrease (by 2–4 times) in the production of IFN-α and IFN-γ, inhibition of the functional activity of T-lymphocytes was revealed in the determination of surface markers CD3, CD8, CD25, CD38, CD95. After a course of treatment with amixin, the production of IFN-α and IFN-γ, the content of T-lymphocytes and their subpopulations normalized, the concentration of estradiol receptors in the cytosol of endometrial tissue in patients with endometrial hyperplasia and adenocarcinoma significantly decreased. The multifaceted biological activity of amixin determines the possibility of etiotropic and pathogenetic therapy of this pathology.